Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine
11
1
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
36%
4 trials in Phase 3/4
17%
1 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
Role: collaborator
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
Role: collaborator
YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1
Role: collaborator
Normal Saline Infusion for Stroke After Intravenous Thrombolysis
Role: collaborator
A Study of 3D Visualization Techniques to Improve the Quality and Safety of Robot-assisted Nephron Sparing Surgery for Complex Renal Tumors.
Role: collaborator
The Ratio of Hypnotic to Analgesic Potency of Volatile Anesthetics
Role: lead
USG Block of Cutaneous Nerves of the Arm
Role: lead
Analgesia for Clavicular Fracture and Surgery
Role: lead
US-Guided Superficial Cervical Plexus Block
Role: lead
Xingnaojing for Mild-to-severe Acute Ischemic Stroke
Role: collaborator
Study on Continuous Intravenous of Unfractionated Heparin (UFH) to Treat Progressive Cerebral Infarction
Role: lead
All 11 trials loaded